These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29427176)

  • 41. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic impact of biologic utilization patterns in patients with psoriatic arthritis.
    Schwartzman S; Li Y; Zhou H; Palmer JB
    Clin Rheumatol; 2017 Jul; 36(7):1579-1588. PubMed ID: 28474139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maintenance of efficacy and safety with subcutaneous golimumab in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors.
    Wakabayashi H; Inada H; Nishioka Y; Hasegawa M; Sudo A; Nishioka K
    Clin Rheumatol; 2017 Apr; 36(4):941-946. PubMed ID: 27942977
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
    l'Ami MJ; Kneepkens EL; Nurmohamed MT; Krieckaert CLM; Visman IM; Wolbink GJ
    Clin Exp Rheumatol; 2017; 35(3):431-437. PubMed ID: 28079512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
    Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y
    N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.
    Keystone EC; Genovese MC; Hall S; Bae SC; Han C; Gathany TA; Xu S; Zhou Y; Leu JH; Hsia EC
    J Rheumatol; 2016 Feb; 43(2):298-306. PubMed ID: 26669912
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study.
    Lan JL; Chou SJ; Chen DY; Chen YH; Hsieh TY; Young M
    J Formos Med Assoc; 2004 Aug; 103(8):618-23. PubMed ID: 15340661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
    Porter D; van Melckebeke J; Dale J; Messow CM; McConnachie A; Walker A; Munro R; McLaren J; McRorie E; Packham J; Buckley CD; Harvie J; Taylor P; Choy E; Pitzalis C; McInnes IB
    Lancet; 2016 Jul; 388(10041):239-47. PubMed ID: 27197690
    [TBL] [Abstract][Full Text] [Related]  

  • 49. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO-MORE study.
    Pal S; Veeravalli SC; Das SK; Shobha V; Uppuluri RR; Dharmanand BG; Nadkar M; Hsia E; Fei K; Yao R; Khalifa A
    Int J Rheum Dis; 2016 Nov; 19(11):1083-1092. PubMed ID: 27457311
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of golimumab as add-on therapy to standard disease-modifying antirheumatic drugs: Results of the GO-MORE study in the Polish population.
    Jeka S; Batko B; Korkosz M; Majdan M; Kwiatkowska B; Dankiewicz-Fares I; Sobiecki JM; Samborski W
    Adv Clin Exp Med; 2018 Apr; 27(4):493-499. PubMed ID: 29558044
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
    Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
    Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.
    Kaeley GS; Nishio MJ; Goyal JR; MacCarter DK; Wells AF; Chen S; Kupper H; Kalabic J
    Arthritis Rheumatol; 2016 Nov; 68(11):2584-2592. PubMed ID: 27214046
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
    Favalli EG; Becciolini A; Carletto A; Conti F; Amato G; Fusaro E; Quartuccio L; Egan CG; Lo Monaco A; Benucci M; Salaffi F; Semeraro A; Parisi S; Ceccarelli F; Piazza I; Foti R
    Rheumatol Int; 2020 Feb; 40(2):263-272. PubMed ID: 31435754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial.
    Kaeley GS; Evangelisto AM; Nishio MJ; Goss SL; Liu S; Kalabic J; Kupper H
    J Rheumatol; 2016 Aug; 43(8):1480-9. PubMed ID: 27307526
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Power Doppler ultrasound monitoring of response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis.
    Iagnocco A; Finucci A; Ceccarelli F; Perricone C; Iorgoveanu V; Valesini G
    Rheumatology (Oxford); 2015 Oct; 54(10):1890-6. PubMed ID: 26070937
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
    Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160.
    Smolen JS; Kay J; Landewé RB; Matteson EL; Gaylis N; Wollenhaupt J; Murphy FT; Zhou Y; Hsia EC; Doyle MK
    Ann Rheum Dis; 2012 Oct; 71(10):1671-9. PubMed ID: 22459542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
    Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
    RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.